Sagimet Biosciences Inc. SGMT
9.70 USD +0.58 (+6.33%)
Nov 6, 2026, 3:13 PM EST
9.19 Day range 9.76
4.50 52-week range 11.45
- YTD
- +63.80%
- 1 year
- +26.10%
- Market cap
- 686.40M
- Revenue (ttm)
- 2.00M
- EPS (ttm)
- -1.27
- Shares out
- 30.67M
- Forward P/E
- -1.40
- YTD return
- +63.80%
- 1-year return
- +26.10%
- Volume
- 481.19K
- Avg volume
- 1.28M
- Open
- 9.20
- Previous close
- 9.12
- Day's range
- 9.19 – 9.76
- 52-week range
- 4.50 – 11.45
- Price target
- 29.14 (+200.5%)
- Earnings date
- Aug 14, 2024
5D -0.23 (-2.32%)
Key statistics
- Enterprise value
- -906.07K
- PEG ratio
- 0.00
- Price / sales
- 80.01
- Price / book
- 1.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -14.40M
- Total cash
- 166.37M
- Total debt
- 153.00K
- Return on equity
- -29.32%
- Short % of float
- 15.48%
- 50-day average
- 5.28
- 200-day average
- 4.27
Analyst view
Price target (mean) 29.14 +200.5% upside
Now 9.70
- Target (low)
- 6.00
- Target (mean)
- 29.14
- Target (high)
- 67.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy3
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.632.
Financials — quick view
SGMT Revenue — quarterly 0
SGMT Net income — quarterly -13.95M
SGMT EPS — quarterly -0.26
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.47 | -0.45 | +0.02 | +4.26% |
| Aug 14, 2024 | Jun 1, 2024 | -0.34 | -0.25 | +0.09 | +26.47% |
| Aug 14, 2024 | Jun 1, 2024 | -0.34 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.41 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.41 | -0.23 | +0.18 | +43.90% |
| Mar 25, 2024 | Dec 1, 2023 | -0.57 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | Oppenheimer | init | — | Outperform |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | UBS | init | — | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sagimet.com
News
Sagimet Biosciences Doses First Patient In AURORA, Pivotal U.S. Phase 3 Clinical Trial Of Denifanstat In Adults With Moderate To Severe Acne 
Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11 - HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26 - Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38
- Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise - Sagimet Biosciences Prices $115M Offer Of Shares And Warrants At $10.00/Unit
- Sagimet Biosciences Suspends And Terminates August 14 Prospectus Supplement Regarding ATM Sales Agreement With Leerink
- Sagimet Biosciences Announces 52-week Results From The Phase 3 ASC40-304 OLE Trial Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris; Denifanstat Showed Progressive And Sustained Improvements Across All Efficacy Endpoints In The OLE, Including Investigator's Global Assessment Success With A Response Rate Of 57%, 72% Reduction In Total Lesions, And 77% Reduction In Inflammatory Lesions, And Was Generally Well-Tolerated, With No Adverse Event-Related Permanent Discontinuations
Your note
Sign in to keep a note on SGMT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HAPPEL DAVID | Chief Executive Officer | Purchase | Mar 25, 2024 | 639,200 |
| KEMBLE GEORGE | Officer and Director | Sale | Jul 22, 2024 | 118,693 |
| KPCB PBD ASSOCIATES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 17, 2023 | 0 |
| MARTINS EDUARDO BRUNO | Officer | Sale | Jul 18, 2024 | 81,213 |
| NEW ENTERPRISE ASSOCIATES 13, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 17, 2023 | 0 |
| PARSEY MERDAD V | Director | Stock Award(Grant) | Jul 17, 2023 | 12,794 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 7.80% | 2,393,928 | 11.90M | Sep 29, 2024 |
| NEA Management Company, LLC | 6.52% | 2,000,275 | 9.94M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 5.46% | 1,673,877 | 8.32M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 4.50% | 1,381,898 | 6.87M | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 4.49% | 1,378,358 | 6.85M | Sep 29, 2024 |
| Citadel Advisors Llc | 3.96% | 1,215,871 | 6.04M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.49% | 763,985 | 3.80M | Sep 29, 2024 |
| BlackRock Health Sciences Term Trust | 1.33% | 408,120 | 2.03M | Sep 29, 2024 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 0.99% | 302,930 | 1.51M | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 246,106 | 1.22M | Sep 29, 2024 |
| Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 0.60% | 185,000 | 919.45K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 133,428 | 663.14K | Oct 30, 2024 |